15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment
Key Takeaways
- Burn wounds requiring >14-21 days to achieve complete re-epithelialization exhibit an exponential rise in hypertrophic scar (HTS) development, reaching an incidence of 70% to >80%.
- The molecular pathophysiology of HTS is governed by prolonged inflammatory cytokine signaling (particularly TGF-β1 and TGF-β2), excessive differentiation of fibroblasts into α-SMA-positive myofibroblasts, failure of myofibroblast apoptosis, and dense nodular whorls of disorganized type III collagen.
- Hypertrophic scars are raised, erythematous, and rigid, remaining confined within the original wound boundaries and undergoing partial maturation over 1-2 years, whereas keloids actively invade surrounding uninjured dermis, lack spontaneous regression, and exhibit strong genetic/familial predisposition.
- The Vancouver Scar Scale (VSS) is the gold standard clinical tool assessing four domains: Vascularity (0-3), Pigmentation (0-3), Pliability (0-5), and Height/Thickness (0-3), yielding a composite severity score from 0 (normal) to 13 (maximum scar severity).
- The Patient and Observer Scar Assessment Scale (POSAS) complements the VSS by incorporating subjective patient symptoms (pruritus, neuropathic pain, stiffness) alongside observer parameters.
15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment
Core Knowledge: Hypertrophic scarring (HTS) is the most prevalent, distressing, and functionally debilitating long-term complication of deep thermal injury. Occurring in over $70%\text{--}80%$ of burn wounds that require longer than $21\text{ days}$ to heal, HTS represents a state of pathological fibroproliferation driven by persistent chronic inflammation, sustained transforming growth factor-beta (TGF-$\beta$) signaling, failure of myofibroblast apoptosis, and excessive deposition of disorganized extracellular matrix (ECM). Accurate, objective clinical monitoring using validated tools like the Vancouver Scar Scale (VSS) is essential for guiding compression, topical therapies, and surgical reconstruction.
1. Pathophysiology and Kinetics of Hypertrophic Scar Formation
Normal cutaneous wound healing progresses through three overlapping phases: inflammation, proliferation (granulation and re-epithelialization), and remodeling. In hypertrophic scarring, the inflammatory and proliferative phases fail to terminate, creating an ongoing loop of excessive matrix synthesis and contraction.
TIME TO HEALING VS. HYPERTROPHIC SCAR RISK
┌───────────────────────┬────────────────────────────────────────────────┐
│ Time to Complete │ Incidence & Severity of Hypertrophic Scarring │
│ Re-epithelialization │ │
├───────────────────────┼────────────────────────────────────────────────┤
│ < 14 Days │ Minimal Risk (<10%–15%); minimal dermal damage;│
│ (Superficial partial) │ Normal parallel collagen remodeling. │
├───────────────────────┼────────────────────────────────────────────────┤
│ 14 to 21 Days │ Moderate Risk (30%–35%); transitional zone; │
│ (Mid-dermal partial) │ Prophylactic scar management recommended. │
├───────────────────────┼────────────────────────────────────────────────┤
│ > 21 Days │ High to Severe Risk (70%–85%+); profound │
│ (Deep partial / full) │ chronic inflammation; aggressive HTS standard. │
└───────────────────────┴────────────────────────────────────────────────┘
Molecular Drivers of Hypertrophic Scarring:
- Prolonged TGF-$\beta$ Signaling: Transforming Growth Factor-beta isoforms play distinct roles. TGF-$\beta_1$ and TGF-$\beta_2$ are potent pro-fibrotic cytokines that drive fibroblast proliferation, induce myofibroblast differentiation, and stimulate massive collagen synthesis while suppressing matrix metalloproteinases (MMPs). In contrast, TGF-$\beta_3$ promotes scarless fetal healing and matrix organization.
- Inflammatory Mediators: Sustained local infiltration of mast cells (releasing histamine and promoting pruritus), macrophages, and T-lymphocytes continuously secretes platelet-derived growth factor (PDGF), connective tissue growth factor (CTGF), and interleukin-6 ($IL-6$), maintaining a perpetual proliferative state.
- Angiogenesis and Microvascular Hyperemia: Endothelial hyperactivity and vascular endothelial growth factor (VEGF) overexpression produce abundant, irregular microvessels, giving active hypertrophic scars their characteristic intense purple-red erythema.
2. Cellular Mechanisms: The Myofibroblast and Collagen Disorganization
The myofibroblast is the key cellular effector in hypertrophic scar pathology. Originating from resident dermal fibroblasts and circulating pericytes under the influence of mechanical tension and TGF-$\beta_1$, myofibroblasts express large intracellular bundles of alpha-smooth muscle actin ($\alpha$-SMA).
NORMAL DERMIS VS. HYPERTROPHIC SCAR
┌────────────────────────────────────────┬────────────────────────────────────────┐
│ NORMAL DERMAL ARCHITECTURE │ HYPERTROPHIC BURN SCAR ARCHITECTURE │
├────────────────────────────────────────┼────────────────────────────────────────┤
│ • Collagen Ratio: 4:1 (Type I : III) │ • Collagen Ratio: Altered (High Type III)│
│ • Fiber Arrangement: Relaxed, parallel │ • Fiber Arrangement: Dense, nodular, │
│ 'basketweave' orientation │ swirling whorls & tight bundles │
│ • Cellularity: Low; quiescent fibrocytes│ • Cellularity: Extreme; active myofibro-│
│ • Microvasculature: Organized capillaries│ blasts resisting apoptosis │
│ • Mechanical Property: Supple, elastic │ • Microvasculature: Hypervascular, leaky│
│ │ • Mechanical Property: Rigid, unyielding│
└────────────────────────────────────────┴────────────────────────────────────────┘
In physiological wound healing, myofibroblasts undergo programmed cell death (apoptosis) once wound closure is achieved. In hypertrophic scarring, myofibroblast apoptosis is pathologically blocked, causing persistent cellular contraction and continuous, excessive secretion of disorganized collagen whorls that create rigid, raised scar nodules.
3. Differentiating Hypertrophic Scars from Keloids
Although both represent fibroproliferative disorders of wound healing, hypertrophic scars and keloids possess distinct clinical, histological, and genetic characteristics that dictate different therapeutic approaches.
| Diagnostic Feature | Hypertrophic Scar (HTS) | Keloid |
|---|---|---|
| Boundaries | Confined strictly within the borders of the original burn wound or surgical incision. | Invades into surrounding normal skin, extending far beyond original wound margins. |
| Onset Timeline | Emerges rapidly within 4 to 8 weeks post-injury; peaks around 6 months. | Emerges late, often months to years after minor cutaneous trauma or spontaneously. |
| Natural History | Undergoes gradual maturation and regression over 12 to 24 months (softens, flattens, pales). | Does not regress spontaneously; exhibits continuous, progressive outgrowths over years. |
| Predisposing Sites | Flexor joint surfaces, anterior chest, neck, shoulders, areas of high mechanical skin tension. | Earlobes, deltoid, pre-sternum, upper back; less dependent on physical tension lines. |
| Genetic Background | Occurs across all races; equal male/female; driven primarily by wound depth and healing delay ($>21\text{ days}$). | Strong familial and ethnic predilection (predominantly individuals with darker skin pigmentation; Fitzpatrick types IV–VI). |
| Histology | Collagen arranged in discrete nodular whorls; contains active myofibroblasts with $\alpha$-SMA. | Large, thick, hyalinized acelluar collagen bundles ('keloidal collagen'); lacks distinct nodules. |
| Response to Excision | Low recurrence after excision if combined with tension relief, grafting, and pressure therapy ($<20%$). | Extremely high recurrence rate ($>50%\text{--}80%$) when surgically excised alone. |
4. Objective Scar Assessment: The Vancouver Scar Scale (VSS)
The Vancouver Scar Scale (VSS) (originally introduced by Sullivan in 1990) is the internationally recognized gold standard clinical tool for quantitative, longitudinal assessment of burn scar severity.
VANCOUVER SCAR SCALE (VSS) SCORING MATRIX
┌────────────────────────────────────────────────────────────────────────┐
│ TOTAL SCORE RANGE: 0 (Normal Skin) to 13 (Maximum Scar Severity) │
├──────────────┬───────┬─────────────────────────────────────────────────┤
│ Parameter │ Score │ Clinical Description & Diagnostic Criteria │
├──────────────┼───────┼─────────────────────────────────────────────────┤
│ VASCULARITY │ 0 │ Normal: Color resembles remainder of body │
│ │ 1 │ Pink: Slight increase in microvascular flow │
│ │ 2 │ Red: High vascularity, prominent capillary loop │
│ │ 3 │ Purple: Extreme vascularity, congestive stasis │
├──────────────┼───────┼─────────────────────────────────────────────────┤
│ PIGMENTATION │ 0 │ Normal: Color matches surrounding native skin │
│ │ 1 │ Hypopigmentation: Loss of melanin pigment │
│ │ 2 │ Mixed Pigmentation: Mottled hyper/hypo regions │
│ │ 3 │ Hyperpigmentation: Excessive dark melanin deposit│
├──────────────┼───────┼─────────────────────────────────────────────────┤
│ PLIABILITY │ 0 │ Normal: Normal cutaneous elasticity and recoil │
│ │ 1 │ Supple: Flexible with minimal resistance │
│ │ 2 │ Yielding: Gives way under moderate pressure │
│ │ 3 │ Firm: Solid, unyielding, resistant to movement │
│ │ 4 │ Ropes / Banding: Thick fibrous cords blanching │
│ │ 5 │ Contracture: Permanent flexion/extension deficit│
├──────────────┼───────┼─────────────────────────────────────────────────┤
│ HEIGHT / │ 0 │ Normal / Flat: Flush with adjacent normal skin │
│ THICKNESS │ 1 │ < 2 mm: Mild elevation │
│ │ 2 │ 2 mm to 5 mm: Moderate thickness │
│ │ 3 │ > 5 mm: Severe hypertrophy / massive protrusion │
└──────────────┴───────┴─────────────────────────────────────────────────┘
Clinical Application and VSS Tracking:
- Serial Measurements: The burn nurse or therapist performs VSS ratings at regular intervals (e.g., monthly during compression garment wear) to objectively quantify scar maturation.
- Tracking Remodeling: As a hypertrophic scar matures, the VSS score systematically declines. Vascularity shifts from purple (3) or red (2) to pink (1) and eventually normal (0) as capillary density regresses. Pliability improves from firm (3) to supple (1), and height flattens from $>5\text{ mm}$ (3) to flat (0).
5. Comprehensive Scar Evaluation Tools: POSAS & Modern Metrics
While the VSS provides an objective observer rating, it does not assess subjective patient symptoms. The Patient and Observer Scar Assessment Scale (POSAS) addresses this limitation by incorporating two distinct scales:
- Observer Scale: Rates vascularity, pigmentation, thickness, relief, pliability, and surface area (each scored 1 to 10).
- Patient Scale: Evaluates the survivor's subjective experience, scoring pain, pruritus (itching), color difference, stiffness, thickness, and irregularity (each scored 1 to 10).
OBJECTIVE BIOENGINEERING SCAR INSTRUMENTS
┌────────────────────┬───────────────────────────────────────────────────┐
│ Instrument │ Objective Quantitative Parameter Measured │
├────────────────────┼───────────────────────────────────────────────────┤
│ Cutometer® │ Measures vertical skin displacement via suction to│
│ │ quantify true biomechanical elasticity & recoil. │
├────────────────────┼───────────────────────────────────────────────────┤
│ Mexameter® / │ Quantifies narrow-band spectrophotometric melanin │
│ Minolta Chromameter│ (pigmentation) and hemoglobin (erythema/vascular).│
├────────────────────┼───────────────────────────────────────────────────┤
│ High-Frequency │ Measures scar thickness and depth in millimeters │
│ Ultrasound (20MHz) │ with sub-millimeter anatomical precision. │
└────────────────────┴───────────────────────────────────────────────────┘
A burn nurse is evaluating a mature donor site scar and an adjacent deep flame burn scar on a patient's right thigh 4 months post-injury. The scar is bright red, raised 4 mm above the surrounding skin, yields only under firm manual pressure, and exhibits areas of mottled hyperpigmentation. According to the Vancouver Scar Scale (VSS), what is the calculated score for this scar?
Which of the following cellular and molecular mechanisms is primarily responsible for the pathological development of hypertrophic scarring following deep partial-thickness burns that take >21 days to heal?
A clinician is differentiating a hypertrophic burn scar from a keloid on a patient's shoulder. Which clinical feature strongly supports the diagnosis of a hypertrophic scar rather than a keloid?